Fluidigm Corporation (FLDM) Insider Purchases $60,000.00 in Stock
Fluidigm Corporation (NASDAQ:FLDM) insider Steven Mcphail purchased 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was bought at an average price of $3.00 per share, with a total value of $60,000.00. Following the transaction, the insider now directly owns 27,842 shares in the company, valued at $83,526. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Fluidigm Corporation (NASDAQ FLDM) traded up 14.02% during trading on Tuesday, hitting $3.09. The company had a trading volume of 873,968 shares. The company’s market capitalization is $90.52 million. The firm has a 50-day moving average of $3.84 and a 200 day moving average of $5.08. Fluidigm Corporation has a 12-month low of $2.52 and a 12-month high of $9.65.
Fluidigm Corporation (NASDAQ:FLDM) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.02. Fluidigm Corporation had a negative return on equity of 104.38% and a negative net margin of 74.05%. The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $23.50 million. During the same period in the previous year, the firm earned ($0.63) earnings per share. The firm’s quarterly revenue was down 15.2% compared to the same quarter last year. On average, equities research analysts forecast that Fluidigm Corporation will post ($2.19) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/fluidigm-corporation-fldm-insider-purchases-60000-00-in-stock.html.
Several large investors have recently made changes to their positions in FLDM. American International Group Inc. boosted its position in Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock worth $102,000 after buying an additional 1,187 shares during the last quarter. AQR Capital Management LLC acquired a new position in Fluidigm Corporation during the fourth quarter worth about $119,000. Stoneridge Investment Partners LLC boosted its position in Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock worth $144,000 after buying an additional 1,013 shares during the last quarter. Wells Fargo & Company MN boosted its position in Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock worth $146,000 after buying an additional 3,327 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock worth $151,000 after buying an additional 632 shares during the last quarter. 91.66% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently weighed in on FLDM. Zacks Investment Research lowered Fluidigm Corporation from a “buy” rating to a “hold” rating in a research report on Monday, April 10th. ValuEngine lowered Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.